IMVP-16                                              lymphoma(93)
 _________________________________________________________________
  ifosfamide...... 1,000 mg/sqm/day IV from day 1 to day 5.
  methotrexate.... 30 mg/sqm IM on day 3 and day 10.
  etoposide....... 100 mg/sqm/day IV from day 1 to day 3.
  FREQUENCY....... Repeat cycle every 21 days.


  reference...
    Cabanillas F.  Hagemeister FB.  Bodey GP.  Freireich EJ. 
    IMVP-16: an effective regimen for patients with lymphoma who 
    have relapsed after initial combination chemotherapy. Blood.  
    60(3):693-7, 1982 Sep. 
  abstract...
    Results of second-line chemotherapy regimens against lymphoma 
    have usually been poor. In this study, we used a combination 
    of ifosfamide, methotrexate, and VP-16 to treat 52 patients 
    with lymphoma who had either relapsed or who had failed to 
    attain a complete remission on front-line treatment. 
    Thirty-two patients (62%) responded (CR 37%, PR 25%) and 10 
    (19%) had a minor response. The median relapse-free interval 
    of the responding patients was 12 mo, and the median survival 
    of the whole group was 15 mo. Of the 18 patients who achieved 
    complete remission, 10 still remain free of any evidence of 
    disease. The factor that best predicted for response to 
    IMVP-16 was the quality of the remission achieved on 
    front-line therapy. In view of the poor prognosis associated 
    with recurrent lymphoma, the results obtained with this study 
    are considered most encouraging. Patients with recurrent 
    lymphoma can be successfully salvaged by the use of this 
    combination regimen, especially if introduced early after 
    relapse or preferably before progressive disease develops.